Abstract
In the recent years has being a great expansion of new preclinical models of colorectal cancer (CRC) based on patient-derived cells, from ex vivo 2D cell lines, toward 3D tumoroids or animal xenografts. These new technologies have been key to overcome historical limitations in CRC research such as precision medicine, pharmacogenomic screenings, or investigating mechanism of drug resistance. Here we describe a method to generate metastatic CRC in mice with patient-derived cells and the evaluation of drug response with computerized tomography. CRC at this advanced stage is the most frequent situation in patients enrolled in therapies with novel drugs that in some cases are designed to target metastatic cells. Therefore, these orthotopic models could be considered the best to recapitulate advance CRC and are therefore becoming instrumental to investigate the biology behind drug-response in metastatic disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Byrne AT, Alferez DG, Amant F, Annibali D, Arribas J, Biankin AV et al (2017) Interrogating open issues in cancer precision medicine with patient-derived xenografts (ReviewResearch support, non-U.S. Gov't research support, N.I.H., extramural). Nat Rev Cancer 17(4):254–268. https://doi.org/10.1038/nrc.2016.140
Puig I, Chicote I, Tenbaum SP, Arques O, Herance JR, Gispert JD et al (2013) A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells (research support, non-U.S. Gov't). Clin Cancer Res 19(24):6787–6801. https://doi.org/10.1158/1078-0432.CCR-12-1740
Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, Davis T et al (2014) Self-renewal as a therapeutic target in human colorectal cancer (research support, non-U.S. Gov't). Nat Med 20(1):29–36. https://doi.org/10.1038/nm.3418
O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice (research support, non-U.S. Gov't). Nature 445(7123):106–110. https://doi.org/10.1038/nature05372
Puig I, Tenbaum SP, Chicote I, Arques O, Martinez-Quintanilla J, Cuesta-Borras E et al (2018) TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. J Clin Invest 128(9):3887–3905. https://doi.org/10.1172/JCI96393
Acknowledgments
We acknowledge Cellex Foundation, CIBERONC network, and Instituto de Salud Carlos III for their support.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Chicote, I., Cámara, J.A., Palmer, H.G. (2020). Advanced Colorectal Cancer Orthotopic Patient-Derived Xenograft Models for Cancer and Stem Cell Research. In: Ordóñez-Morán, P. (eds) Intestinal Stem Cells. Methods in Molecular Biology, vol 2171. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0747-3_22
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0747-3_22
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0746-6
Online ISBN: 978-1-0716-0747-3
eBook Packages: Springer Protocols